The European Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending marketing authorisation for Kostaive, a self-replicating (replicon) mRNA injection developed by Arcturus Therapeutics. The final decision for regulatory approval now rests with the European Commission:
Japan had already approved these injections last year. In November 2023, Japan’s Ministry of Health, Labor and Welfare (MHLW) fully approved CSL and Arcturus Therapeutics’ replicon shot, KostaiveARCT-154. Despite enormous safety concerns, Japan’s MHLW approved the updated booster shot in September 2024 to target the JN.1 lineage of Omicron subvariants.
During the clinical trials for Kostaive, five deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90% of injected participants experienced adverse events, with 74.5% reporting systemic reactions and 15.2% requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions.
Here’s a map plotting the properties that the Dept. of Homeland Security has said are associated with Asian Transnational Criminal Organizations, aka Chinese mafia, in Maine.
The entire Chinese mafia problem sprung up on @GovJanetMills’ watch, right after the Consul of China’s Consulate in NYC, Huang Ping, attended Mills’ inauguration.
I told you here about Pfizer’s abstract of its Interim Report 5, showing at least 23-40% higher risk of some heart-related conditions in the vaccinated, but that the MHRA, the U.K. medicines regulator, was withholding publication of the full report. As I said at the time : “In summary, if, as I suspect, MHRA is worried by the results in Pfizer’s ‘Interim Report 5’ then no wonder it is sitting on it.”
Well, MHRA is still sitting on the report but I’ve managed to obtain a copy. It looks like I was right – the detailed results in the full report are even more worrying than the Hazard Ratios in the abstract which I reported last time (below).
American Buddhist Net 